4
22
1
↑4
↓22
—1
Evidence suggests MDMA maydecreasePtsd symptoms.
24 studies (27 claims)
Strong consensus
Typical effective dose 125 (125–125) mgacross 6 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| full-dose MDMA (100-125 mg) | Decreases - significantly reduced | PTSD symptoms | Human | all groups | 30 mg, 75 mg, or 125 mg in two 8-hour sessions, followed by three 100-125 mg sessions in an open-label crossover. | 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.cited 227× |
| Active doses (75 mg and 125 mg) of MDMA with adjunctive psychotherapy | Decreases - effective and well tolerated in reducing | PTSD symptoms | Human | veterans and first responders | 30 mg, 75 mg, or 125 mg in two 8-hour sessions, followed by three 100-125 mg sessions in an open-label crossover. | 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.cited 227× |
| MDMA-assisted psychotherapy | Decreases - remained lower than baseline | Posttraumatic stress disorder symptoms | Human | people with chronic posttraumatic stress disorder | 40 mg, 100 mg, and 125 mg administered during eight-hour psychotherapy sessions (two sessions for active doses, with additional open-label sessions). | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.cited 123× |
| MDMA-assisted psychotherapy | Decreases - reduces | posttraumatic stress disorder symptoms | Human | people with chronic posttraumatic stress disorder | 40 mg, 100 mg, and 125 mg administered during eight-hour psychotherapy sessions (two sessions for active doses, with additional open-label sessions). | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.cited 123× |
| MDMA-assisted psychotherapy | Decreases - demonstrated effectiveness and acceptable safety in reducing | PTSD symptoms | Human | participants in Phase 2 trials | Not specified in the abstract. | MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?cited 112× |
| MDMA-assisted psychotherapy | Decreases - efficacious and well tolerated | PTSD symptoms | Human | adults with PTSD | 75-125 mg MDMA in two or three 8-hour sessions spaced a month apart. | MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.cited 199× |
| MDMA-assisted psychotherapy | Decreases - reduced | PTSD symptoms | Human | participants | 75-125 mg MDMA, administered in two to three active doses during psychotherapy sessions. | Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.cited 91× |
| MDMA-assisted psychotherapy | Decreases - has been shown to greatly improve | PTSD symptoms | Human | individuals with PTSD | — | Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.cited 27× |
| MDMA-assisted psychotherapy | Decreases - reduces | PTSD symptoms | Human | — | One or two oral doses of MDMA per session, administered in two or three sessions. | [MDMA-assisted therapy for PTSD]. |
| MDMA-assisted psychotherapy | Decreases - can reduce | PTSD symptoms | Human | PTSD patients | Not specified | MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence.cited 3× |
| MDMA-assisted psychotherapy | No effect - changes in Openness played a moderating role | relationship between reduced PTSD symptoms and MDMA treatment | Human | chronic, treatment-resistant PTSD | Not specified | Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.cited 77× |
| MDMA-assisted psychotherapy | Decreases - demonstrated rapid and durable improvement in | social anxiety symptoms | Human | autistic adults | 75 to 125 mg during two 8-hour psychotherapy sessions. | Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.cited 129× |
| MDMA-assisted psychotherapy | Increases - may improve | symptoms | Human | patients with PTSD | Not specified in the abstract. | The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.cited 3× |
| MDMA-assisted psychotherapy | Decreases - can reduce | symptoms of PTSD | Human | — | Not specified | Can MDMA play a role in the treatment of substance abuse?cited 17× |
| MDMA-assisted psychotherapy | Decreases - with a large effect size at reducing the symptoms | symptoms of PTSD | Human | individuals with treatment-refractory PTSD | Not specified in the abstract. | Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis.cited 33× |
| MDMA (ecstasy) | Increases - were more likely to report ≥3 DSM-IV dependence symptoms | dependence symptoms | Human | last year users | Not specified | Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users.cited 34× |
| MDMA (ecstasy) | Increases - were more likely to report ≥3 DSM-IV dependence symptoms | dependence symptoms | Human | last year users | Not specified | Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users.cited 34× |
| MDMA (ecstasy) | Increases - were more likely to report ≥3 DSM-IV dependence symptoms | dependence symptoms | Human | last year users | Not specified | Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users.cited 34× |
| MDMA | Decreases - were associated with medium effect sizes | depressive symptoms | Human | adult patients with depressive symptoms | Not available | The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. |
| MDMA | No effect - were not statistically significant | depressive symptoms | Human | adult patients with depressive symptoms | Not available | The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. |
| MDMA | Decreases - little chance of diversion, accidental or intentional overdose, or withdrawal symptoms | diversion, overdose, withdrawal symptoms | Human | — | Administered in up to three monthly 8-hour sessions (specific dosage not mentioned). | Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.cited 5× |
| MDMA | Decreases - hold potential beyond | PTSD symptoms | Human | — | Not specified | MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.cited 7× |
| MDMA-assisted therapy (MDMA-AT) | Decreases - significantly reduced | ED symptoms | Human | participants with severe PTSD | Not specified in the abstract. | MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.cited 31× |
| MDMA-assisted therapy | Decreases - resulted in significant improvement in | PTSD symptoms | Human | human-subject studies | Not specified | Review of potential psychedelic treatments for PTSD.cited 18× |
| MDMA-assisted therapy | Decreases - is being explored as a novel treatment for PTSD that potentially offers rapid symptom improvement | PTSD symptoms | Human | patients with PTSD | Not mentioned | MDMA for treatment of PTSD and neurorehabilitation in military populations. |
| MDMA-assisted therapy (MDMA-AT) | Decreases - demonstrated significant reductions in | PTSD symptoms | Human | participants | Not specified in the abstract. | MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward. |
| MDMA-assisted therapy | No effect - will examine the effect | symptoms of anxiety and depression | Human | advanced-stage cancer | 120 mg MDMA (+ 60 mg optional supplemental dose) per session. | Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.cited 2× |